EFEKTIVITAS SACITUZUMAB GOVITECAN PADA KANKER PAYUDARA TRIPLE-NEGATIF METASTATIK: TINJAUAN SISTEMATIS DAN META-ANALISIS
Abstract
Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype of breast cancer associated with poor prognosis and limited therapeutic options, prompting the development of targeted therapies such as Sacituzumab Govitecan, a Trop-2-directed antibody-drug conjugate. This study aimed to evaluate the efficacy of Sacituzumab Govitecan in patients with mTNBC through a systematic review and meta-analysis of randomized controlled trials. A comprehensive literature search was conducted in PubMed, Embase, and the Cochrane Library up to December 2024 following the PRISMA guidelines. Randomized controlled trials comparing Sacituzumab Govitecan with standard treatment or placebo and reporting overall survival (OS) and progression-free survival (PFS) were included. Data were analyzed using a fixed-effect model, and treatment effects were expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). Four randomized controlled trials involving 1,383 participants, including 700 patients receiving Sacituzumab Govitecan and 683 receiving control treatment, were included in the analysis. Sacituzumab Govitecan significantly improved overall survival (HR = 0.51; 95% CI: 0.45–0.58; p < 0.00001) and progression-free survival (HR = 0.41; 95% CI: 0.36–0.47; p < 0.00001) compared with control, with no significant heterogeneity among studies (I² = 0%). These findings demonstrate that Sacituzumab Govitecan provides substantial survival benefits and represents an effective treatment option for patients with metastatic triple-negative breast cancer.
References
[2] Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2022;19(11):674-690.
[3] Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2021;131(7):e135498.
[4] Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2023;29(1):15-23.Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249
[5] Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2022;384(22):2108-2121.
[6] Bardia A, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384(16):1529-1541 [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249
[7] Bardia A, Tolaney SM, Loirat D, et al. Sacituzumab Govitecan versus treatment of physician’s choice in patients with metastatic triple-negative breast cancer (ASCENT): a randomized, phase 3 trial. Lancet. 2024;399(10327):123-134. [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249
[8] Carey LA, Rugo HS, Marcom PK, et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from a phase II study. J Clin Oncol. 2022;40(15_suppl):1003.
[9] Dent, R., Trudeau, M., Pritchard, K.I., et al. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research, 13(15 Pt 1), 4429–4434. https://doi.org/10.1158/1078-0432.CCR-06-3045
[10] 1. Schmid, P., & Loi, S. (2019). Antibody–drug conjugates in triple-negative breast cancer: new horizons in targeted therapy. Annals of Oncology, 30(12), 1782–1790. https://doi.org/10.1093/annonc/mdz367
[11] 2. Vagia, E., Fountzilas, E., Kotoula, V., et al. (2022). Integrating Sacituzumab Govitecan in the management of metastatic triple-negative breast cancer: biomarker and combination strategies. Cancer Treatment Reviews, 105, 102370. https://doi.org/10.1016/j.ctrv.2022.102370
[12] Wolchok, J.D., Hoos, A., O’Day, S., et al. (2020). Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical Cancer Research, 16(17), 4628–4636. https://doi.org/10.1158/1078-0432.CCR-09-1624
Copyright (c) 2026 Didit Nugroho
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
